“We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer”
THIRD QUARTER IN BRIEF
• Active Biotech provided status update of its clinical naptumomab project on July 5
• Active Biotech’s partner NeoTX hosted KOL webinar on overcoming checkpoint inhibitor resistance on
July 8
EVENTS AFTER THE END OF THE PERIOD
Tasquinimod clinical development in multiple myeloma advanced into combination therapy following completion of the initial phase of the ongoing trial in the US (Oct 3)
Active Biotech and NeoTX announced that the first patient had been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) (Oct 20)
Financial summary
SEK M
Jul-Sep
Jan-Sep
Full-year
2021
2020
2021
2020
2020
Net sales
-
-
-
0.5
6.7
Operating profit/loss
-11.3
-8.3
-33.6
-28.2
-32.3
Profit/loss after tax
-11.2
-8.2
-33.7
-28.2
-32.2
Earnings per share (SEK)
-0.05
-0.05
-0.16
-0.17
-0.19
Cash and cash equivalents (at close of period)
68.4
30.9
26.2
Helén Tuvesson, CEO
Tel: +46 (0)46 19 21 56
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund
Tel: +46 (0)46 19 20 00
The report is also available at .
Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on November 4, 2021 at 08.30 a.m. CET.
Attachment
211104_Interim Report Q3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.